Lung cancer (Amsterdam, Netherlands) · 2025
The influence of body mass index on Tumor Treating Fields therapy in patients with metastatic non-small cell lung cancer: A post-hoc and simulation analysis from the phase III LUNAR study.
СтатьяКлиническое исследование III фазыРандомизированное исследованиеНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Rolfo Christian, Gerber David E, Kotecha Rupesh, Ward Jeffrey P, Akerley Wallace, Weiss Lukas, Naveh Ariel, Shapira Nadav, Leal Ticiana, Langer Corey J, LUNAR study investigators
Аннотация
INTRODUCTION: In the phase III LUNAR study, overall survival (OS) with PD-(L)1 inhibitor or docetaxel was improved by adding Tumor Treating Fields (TTFields) therapy in patients with metastatic non-small cell lung cancer progressing on/after platinum-based therapy. This post-hoc analysis evaluated the effects of body mass index (BMI) on TTFields delivery.
METHODS: OS was assessed in LUNAR patients with BMI < 25 kg/m2 versus ≥ 25 kg/m2. TTFields intensity was evaluated via simulations using three array layouts in computerized phantom models with BMIs of 22, 26, and 30 kg/m2.
RESULTS: In the BMI < 25 kg/m2 subgroup (n = 140), median OS was 11.6 versus 8.2 months (hazard ratio [HR] 0.70 [95 % CI, 0.47─1.04]; p = 0.08) in patients treated with TTFields + PD-(L)1 inhibitor/docetaxel versus PD-(L)1 inhibitor/docetaxel, respectively. In the BMI ≥ 25 kg/m2 subgroup (n = 119), median OS was 13.9 versus 10.1 months, respectively (HR 0.74 [95 % CI, 0.49─1.13]; p = 0.27). No significant interaction effect between BMI subgroups and treatment arm was identified for OS (p = 0.36). Device-related skin AEs occurred in 68 % and 64 % of BMI < 25 kg/m2 and ≥ 25 kg/m2 patients, respectively. Therapeutic field intensities (>1V/cm) were achieved in all lung regions for all simulation models using appropriately sized arrays and layouts.
CONCLUSIONS: In this post-hoc analysis, we found no difference in OS benefit of TTFields therapy between patients with BMI < 25 kg/m2 versus ≥ 25 kg/m2. Simulation data demonstrated the feasibility of delivering TTFields at therapeutic intensities to the lungs regardless of BMI.
METHODS: OS was assessed in LUNAR patients with BMI < 25 kg/m2 versus ≥ 25 kg/m2. TTFields intensity was evaluated via simulations using three array layouts in computerized phantom models with BMIs of 22, 26, and 30 kg/m2.
RESULTS: In the BMI < 25 kg/m2 subgroup (n = 140), median OS was 11.6 versus 8.2 months (hazard ratio [HR] 0.70 [95 % CI, 0.47─1.04]; p = 0.08) in patients treated with TTFields + PD-(L)1 inhibitor/docetaxel versus PD-(L)1 inhibitor/docetaxel, respectively. In the BMI ≥ 25 kg/m2 subgroup (n = 119), median OS was 13.9 versus 10.1 months, respectively (HR 0.74 [95 % CI, 0.49─1.13]; p = 0.27). No significant interaction effect between BMI subgroups and treatment arm was identified for OS (p = 0.36). Device-related skin AEs occurred in 68 % and 64 % of BMI < 25 kg/m2 and ≥ 25 kg/m2 patients, respectively. Therapeutic field intensities (>1V/cm) were achieved in all lung regions for all simulation models using appropriately sized arrays and layouts.
CONCLUSIONS: In this post-hoc analysis, we found no difference in OS benefit of TTFields therapy between patients with BMI < 25 kg/m2 versus ≥ 25 kg/m2. Simulation data demonstrated the feasibility of delivering TTFields at therapeutic intensities to the lungs regardless of BMI.